Osaka, Japan

Hiroaki Shitama


 

 

Average Co-Inventor Count = 7.5

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016-2023

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Hiroaki Shitama: Innovator in Pharmaceutical Chemistry

Introduction

Hiroaki Shitama is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patents. With a total of 4 patents, Shitama's work focuses on compounds that have therapeutic applications.

Latest Patents

One of his latest patents is related to a lysophosphatidic acid derivative. This invention aims to provide a compound that acts as a specific agonist for LPA4 receptors. The pharmaceutical composition containing this compound is useful for the prophylaxis and treatment of diseases associated with angiogenesis abnormalities and vascular disorders. Another notable patent involves a novel pyrrolidine compound that exhibits melanocortin receptor agonist activity. This invention also includes pharmaceutical applications of the pyrrolidine derivative, which has potential therapeutic benefits.

Career Highlights

Hiroaki Shitama has worked with notable organizations such as Mitsubishi Tanabe Pharma Corporation and Osaka University. His experience in these institutions has allowed him to develop and refine his innovative ideas in pharmaceutical research.

Collaborations

Shitama has collaborated with esteemed colleagues, including Kenji Morokuma and Osamu Sakurai. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Hiroaki Shitama's contributions to pharmaceutical chemistry through his innovative patents highlight his role as a key inventor in the field. His work continues to pave the way for advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…